Friday, July 10, 2026

Patent directory · USPTO A61K / A61P

Patents matching “anti-pd-”

25 pharma patents match "anti-pd-" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 25
Index total 30,257
Page 1 / 2

Quick answer

This filtered view shows 25 pharmaceutical patents matching "anti-pd-" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

25 results for “anti-pd-” · 30,257 patents in full index Clear search

  1. WO 2026107143

    COMBINAISON DE DOSES FIXES D'ANTICORPS ANTI-FUCOSYL-GM1 ET D'ANTICORPS ANTI-PD-1 ET SES UTILISATIONS

    BRISTOL MYERS SQUIBB CO [US] · Granted May 21, 2026 · Expires May 16, 2046

    granted
  2. WO 2026057739

    POLYTHÉRAPIE COMPRENANT DES ANTICORPS ANTI-CTLA4 ET DES ANTICORPS ANTI-PD-1 POUR LE TRAITEMENT DU CANCER DE L'OVAIRE RÉSISTANT AU PLATINE

    BIONTECH SE [DE] · Granted Mar 19, 2026 · Expires Mar 14, 2046

    granted
  3. US 12427173

    Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-CTLA-4 and/or anti-PD-1 antibodies to treat solid tumor malignancies

    Biomed Valley Discoveries, Inc. · Granted Sep 30, 2025 · Expires Sep 25, 2045

    granted
  4. US 12338269

    IL-2 superagonists in combination with anti-PD-1 antibodies

    Medicenna Therapeutics Inc. · Granted Jun 24, 2025 · Expires Jun 19, 2045

    granted
  5. TW 202515903

    Anti-PD-1-based treatment before and after surgery

    BEIGENE SWITZERLAND GMBH [CH] · Granted Apr 16, 2025 · Expires Apr 11, 2045

    granted
  6. WO 2025040080

    TRAITEMENT DU CANCER DE L'OESOPHAGE PAR ANTI-LAG3, ANTI-PD-1 ET CHIMIOTHÉRAPIE

    BEIGENE SWITZERLAND GMBH [CH] · Granted Feb 27, 2025 · Expires Feb 22, 2045

    granted
  7. US 12054557

    Combination of anti-PD-1 antibodies and bispecific anti-CD20/anti-CD3 antibodies to treat cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  8. US 12054556

    Anti-PD-L1 antibody and use thereof

    Oricell Therapeutics Co., Ltd. · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  9. US 12053534

    Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  10. US 11993655

    Anti-PD-L1 antibody and use thereof

    Oricell Therapeutics Co., Ltd. · Granted May 28, 2024 · Expires May 23, 2044

    granted
  11. US 11926668

    Anti-PD-1 antibodies for treatment of lung cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted
  12. CA 3245150

    COMBINAISONS AVEC UN ANTICORPS ANTI-CD39 HUMAIN, UN ANTICORPS ANTI-PD-1 HUMAIN ET UNE CHIMIOTHÉRAPIE CONTRE LE CANCER GASTRIQUE

    TRISHULA THERAPEUTICS INC [US] · Granted Sep 7, 2023 · Expires Sep 2, 2043

    granted
  13. US 11566076

    Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected cancers

    Five Prime Therapeutics, Inc. · Granted Jan 31, 2023 · Expires Jan 26, 2043

    granted
  14. US 11542312

    IL-2 superagonists in combination with anti-PD-1 antibodies

    Medicenna Therapeutics Inc. · Granted Jan 3, 2023 · Expires Dec 29, 2042

    granted
  15. US 11421034

    Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer

    Five Prime Therapeutics, Inc. · Granted Aug 23, 2022 · Expires Aug 18, 2042

    granted
  16. US 11324822

    Combination of HDAC inhibitor and anti-PD-1 antibody for treatment of cancer

    Syndax Pharmaceuticals, Inc. · Granted May 10, 2022 · Expires May 5, 2042

    granted
  17. US 11292842

    Anti-PD-1 antibodies for treatment of lung cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 5, 2022 · Expires Mar 31, 2042

    granted
  18. US 11254752

    Methods for treating cancer with bispecific anti-CD3xMUC16 antibodies and anti-PD-1 antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 22, 2022 · Expires Feb 17, 2042

    granted
  19. US 11254746

    Anti-PD-1 monoclonal antibody, and preparation method therefor and application thereof

    SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. · Granted Feb 22, 2022 · Expires Feb 17, 2042

    granted
  20. US 10822414

    Anti-PD-1 antibodies, compositions comprising anti-PD-1 antibodies and methods of using anti-PD-1 antibodies

    Sutro Biopharma, Inc. · Granted Nov 3, 2020 · Expires Oct 29, 2040

    granted
  21. US 10786552

    Il-2Rβ-selective agonists in combination with an anti-CTLA-4 antibody or an anti-PD-1 antibody

    Nektar Therapeutics · Granted Sep 29, 2020 · Expires Sep 24, 2040

    granted
  22. US 10744116

    Detection and treatment of anti-PD-1 therapy resistant metastatic melanomas

    The Regents of the University of California · Granted Aug 18, 2020 · Expires Aug 13, 2040

    granted
  23. US 10736976

    Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 11, 2020 · Expires Aug 6, 2040

    granted
  24. US 10683347

    Treatment of cancer using anti-TGF-β and anti-PD-1 antibodies

    The Regents of the University of California · Granted Jun 16, 2020 · Expires Jun 11, 2040

    granted